摘要
目的探讨瑞舒伐他汀对维持性血透患者心血管疾病发生率的影响。方法 91例患者分成瑞舒伐他汀组及对照组,治疗开始时及30 d、3个月测量血胆固醇、甘油三酯、脂蛋白及高敏C反应蛋白水平并进行比较。结果在瑞舒伐他汀组,各项指标均有显著降低,总胆固醇从(163±53)mg/dl至(142±43)mg/dl(p<0.05);低密度脂蛋白从(90±39)mg/dl到(69±32)mg/dl(p<0.05);非HDL胆固醇从(121±46)mg/dl到(99±39)mg/dl(p<0.05);而高敏C反应蛋白在3个月后也明显降低(p<0.01)。而对照组则无明显变化。结论瑞舒伐他汀在降低维持性血透患者的心血管疾病发生率起着重要作用。
Objective To explore the affect of rosuvatatin on the occurrence of cardiovascular disease in pa- tients undergoing maintaining hemodialysis. Methods 91 patients on hemodialysis were divided into rosuvatatin group and control group, at baseline, 30 days and 3 months, the patient＇s blood cholesterol, triglycerides, lipoprotein and high - sensitivity C - reactive protein level were measured and compared. Results In the rosuvatatin group, all the indexes have significantly reduced, total cholesterol from （163 ± 53 ）mg/dl to （142 ± 43 ） mg/dl （p 〈 0. 05 ） ; Low density lipoprotein from （90 ± 39 ） mg,/dl to （69 ± 32 ） mg/dl （p 〈 0. 05 ） ; The no - HDL cholesterol from （121 ±46） mg/dl to （99 ±39） mg/dl （p 〈0.05） ; And high -sensitivity e -reactive protein in 3 months also re- duced significantly （p 〈 0. 01 ）. And in control group had no significant change. Conclusion Rosuvatatin in reduc- ing the maintenance hemodialysis patients＇ cardiovascular disease incidence rate plays an important role.
出处
《现代医院》
2013年第5期20-22,共3页
Modern Hospitals
